The room matters as much as the molecule

Ask a researcher what makes psychedelic-assisted therapy work and you will rarely hear an answer that is only about pharmacology. You will hear about the preparation, the relationship with the people in the room, the music, the intention, and the weeks of conversation that follow. The drug opens a door. It does not decide what is on the other side.

That idea is older than the modern field. "Set and setting" was popularised by Timothy Leary and colleagues in the early 1960s, and the observation behind it — that the same substance produces wildly different experiences depending on who takes it, in what state, and where — runs through the whole history of psychedelic research. Contemporary researchers have argued that context is not a modifier of the drug's effect but part of the effect itself.

Preparation is treatment, not paperwork

The hours spent before a dosing session — building trust, naming fears, agreeing what care looks like if things become difficult — are not administrative throat-clearing. They are part of the intervention. Every major trial protocol builds them in, and clinicians consistently report that people who arrive prepared, with a relationship already established, tend to move through hard moments rather than being overwhelmed by them.

"Setting" is an ethical claim in disguise

To say setting matters is to say that a vulnerable person, in an unusually open state, is profoundly affected by how they are treated. That is a statement about power before it is a statement about décor.

The question is never only "is this molecule safe?" It is "is this person safe in this room, with these people, under this much openness?"

The field has a documented case of what happens when that question is not taken seriously. In a Phase 2 MDMA trial in Canada, two therapists breached professional boundaries with a participant during a supervised session, and the participant later described further abuse after the trial ended. The case became public in 2021, along with video from the session, and it shaped the scrutiny regulators applied to the therapy component of later trials. It is a reminder that safeguards — screening, two-person care, clear boundaries, recorded sessions, and a plan for the days afterward — are not optional extras. They exist because the same openness that allows healing also removes the defences a person would normally rely on.

What this means if you are considering it

• A credible programme spends real time with you before any dose.
• It can describe, concretely, what happens if you become distressed, and who you can complain to if something goes wrong.
• It never has a single person alone with you during a session.
• It treats the weeks after the session as the main event, not the aftermath.

The molecule will get the headlines. The room is where the work is done.

Sources and further reading

• Hartogsohn I. "Constructing drug effects: a history of set and setting." Drug Science, Policy and Law, 2017.
• Carhart-Harris RL et al. "Psychedelics and the essential importance of context." Journal of Psychopharmacology, 2018.
• Reporting by New York Magazine and the Cover Story: Power Trip podcast (2021–2022) on the Canadian MDMA trial case.
• US FDA advisory committee meeting on midomafetamine (MDMA) for PTSD, June 2024, which discussed the therapy component and participant safety.

This essay is general information, not medical advice.